Search research articles
Contact Us
Filters
Showing results (31-40 of 188) with videos related to
Page
of 19
Sort By:
JAMA Oncology
|
January 4, 2019
Association of Patient Sex With Efficacy of Immune Checkpoint Inhibitors and Overall Survival in Advanced Cancers: A Systematic Review and Meta-analysis
Christopher J D Wallis, Mohit Butaney, Raj Satkunasivam, et al.
Frontiers in Immunology
|
January 1, 2025
NRF-1 transcription factor regulates expression of an innate immunity checkpoint, CD47, during melanomagenesis
Kuldeep Makwana, Edwin J Velazquez, Diego M Marzese, et al.
Oncoimmunology
|
March 14, 2013
Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors
Robert H Vonderheide, Jennifer M Burg, Rosemarie Mick, et al.
Investigational New Drugs
|
April 9, 2016
A phase I study of the investigational NEDD8-activating enzyme inhibitor pevonedistat (TAK-924/MLN4924) in patients with metastatic melanoma
Shailender Bhatia, Anna C Pavlick, Peter Boasberg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 27, 2020
Mogamulizumab in Combination with Durvalumab or Tremelimumab in Patients with Advanced Solid Tumors: A Phase I Study
Dmitriy Zamarin, Omid Hamid, Asha Nayak-Kapoor, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
December 2, 2011
Ipilimumab in treatment-naive and previously treated patients with metastatic melanoma: retrospective analysis of efficacy and safety data from a phase II trial
John A Thompson, Omid Hamid, David Minor, et al.
Investigational New Drugs
|
February 19, 2011
Clinical and pharmacologic evaluation of two dose levels of intetumumab (CNTO 95) in patients with melanoma or angiosarcoma
Steven J O'Day, Anna C Pavlick, Mark R Albertini, et al.
American Journal of Clinical Oncology
|
December 7, 2019
Analysis of Heterogeneity in Survival Benefit of Immunotherapy in Oncology According to Patient Demographics and Performance Status: A Systematic Review and Meta-Analysis of Overall Survival Data
Mohit Butaney, Raj Satkunasivam, Hanan Goldberg, et al.
Journal of Translational Medicine
|
May 12, 2019
The great debate at "Melanoma Bridge 2018", Naples, December 1st, 2018
Paolo A Ascierto, Paolo Bruzzi, Alexander Eggermont, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 11, 2015
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
Dirk Schadendorf, F Stephen Hodi, Caroline Robert, et al.
Page
of 19
Search research articles
Search
Showing results (31-40 of 188) with videos related to
Sort By:
Page
of 19
JAMA Oncology
|
January 4, 2019
Association of Patient Sex With Efficacy of Immune Checkpoint Inhibitors and Overall Survival in Advanced Cancers: A Systematic Review and Meta-analysis
Christopher J D Wallis, Mohit Butaney, Raj Satkunasivam, et al.
Frontiers in Immunology
|
January 1, 2025
NRF-1 transcription factor regulates expression of an innate immunity checkpoint, CD47, during melanomagenesis
Kuldeep Makwana, Edwin J Velazquez, Diego M Marzese, et al.
Oncoimmunology
|
March 14, 2013
Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors
Robert H Vonderheide, Jennifer M Burg, Rosemarie Mick, et al.
Investigational New Drugs
|
April 9, 2016
A phase I study of the investigational NEDD8-activating enzyme inhibitor pevonedistat (TAK-924/MLN4924) in patients with metastatic melanoma
Shailender Bhatia, Anna C Pavlick, Peter Boasberg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 27, 2020
Mogamulizumab in Combination with Durvalumab or Tremelimumab in Patients with Advanced Solid Tumors: A Phase I Study
Dmitriy Zamarin, Omid Hamid, Asha Nayak-Kapoor, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
December 2, 2011
Ipilimumab in treatment-naive and previously treated patients with metastatic melanoma: retrospective analysis of efficacy and safety data from a phase II trial
John A Thompson, Omid Hamid, David Minor, et al.
Investigational New Drugs
|
February 19, 2011
Clinical and pharmacologic evaluation of two dose levels of intetumumab (CNTO 95) in patients with melanoma or angiosarcoma
Steven J O'Day, Anna C Pavlick, Mark R Albertini, et al.
American Journal of Clinical Oncology
|
December 7, 2019
Analysis of Heterogeneity in Survival Benefit of Immunotherapy in Oncology According to Patient Demographics and Performance Status: A Systematic Review and Meta-Analysis of Overall Survival Data
Mohit Butaney, Raj Satkunasivam, Hanan Goldberg, et al.
Journal of Translational Medicine
|
May 12, 2019
The great debate at "Melanoma Bridge 2018", Naples, December 1st, 2018
Paolo A Ascierto, Paolo Bruzzi, Alexander Eggermont, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 11, 2015
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
Dirk Schadendorf, F Stephen Hodi, Caroline Robert, et al.
Page
of 19